KR20140020815A - Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물 - Google Patents

Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물 Download PDF

Info

Publication number
KR20140020815A
KR20140020815A KR1020137003819A KR20137003819A KR20140020815A KR 20140020815 A KR20140020815 A KR 20140020815A KR 1020137003819 A KR1020137003819 A KR 1020137003819A KR 20137003819 A KR20137003819 A KR 20137003819A KR 20140020815 A KR20140020815 A KR 20140020815A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
budesonide
beta
agonist
tiotropium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137003819A
Other languages
English (en)
Korean (ko)
Inventor
지나 말호트라
쉬리니바스 마드후카르 푸란다레
아마르 룰라
Original Assignee
시플라 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시플라 리미티드 filed Critical 시플라 리미티드
Publication of KR20140020815A publication Critical patent/KR20140020815A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137003819A 2010-07-16 2011-07-18 Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물 Ceased KR20140020815A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN2051/MUM/2010 2010-07-16
IN2051MU2010 2010-07-16
IN3157MU2010 2010-11-18
IN3156MU2010 2010-11-18
IN3157/MUM/2010 2010-11-18
IN3156/MUM/2010 2010-11-18
PCT/GB2011/001077 WO2012007729A2 (en) 2010-07-16 2011-07-18 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187022543A Division KR20180091120A (ko) 2010-07-16 2011-07-18 Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
KR20140020815A true KR20140020815A (ko) 2014-02-19

Family

ID=44629226

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137003819A Ceased KR20140020815A (ko) 2010-07-16 2011-07-18 Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물
KR1020187022543A Ceased KR20180091120A (ko) 2010-07-16 2011-07-18 Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187022543A Ceased KR20180091120A (ko) 2010-07-16 2011-07-18 Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물

Country Status (13)

Country Link
US (4) US20130274232A1 (enExample)
EP (2) EP3871676A1 (enExample)
JP (3) JP2013531056A (enExample)
KR (2) KR20140020815A (enExample)
CN (3) CN105412122A (enExample)
AU (1) AU2011278096B2 (enExample)
BR (1) BR112013001119A2 (enExample)
CA (1) CA2805700A1 (enExample)
MX (1) MX2013000642A (enExample)
NZ (1) NZ605920A (enExample)
RU (1) RU2568882C2 (enExample)
WO (1) WO2012007729A2 (enExample)
ZA (1) ZA201300718B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274232A1 (en) 2010-07-16 2013-10-17 Cipla Limited Pharmaceutical Compositions
CN104918604A (zh) * 2012-10-23 2015-09-16 西普拉有限公司 药物组合物
MX368036B (es) * 2013-08-05 2019-09-17 Chemo Res S L Particulas inhalables que comprenden tiotropio e indacaterol.
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
CN104606205A (zh) * 2015-01-13 2015-05-13 段希福 一种奥达特罗和布地奈德的药物组合物及其用途
EP3383366B2 (en) * 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
EA202092976A1 (ru) * 2018-06-04 2021-03-16 Люпин Инк. Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением
US20200215051A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN110051629A (zh) * 2019-05-17 2019-07-26 南京望知星医药科技有限公司 一种用于治疗呼吸疾病的雾化沙丁胺醇溶液及其制备方法
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂
WO2021262675A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
CN116963715A (zh) 2020-09-29 2023-10-27 艾罗克斯医疗有限责任公司 茚达特罗的液体配制品
US20240156734A1 (en) * 2022-11-11 2024-05-16 Michael Farber Simplified Method for Making Shelf Stable Highly Water Soluble Anhydrous Compositions Of Cyclodextrin Complexes of Macrocyclic Lactones

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
SE9900834D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009613D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
CA2456721C (en) * 2001-08-07 2012-03-20 Galephar M/F Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
CA2467061A1 (en) 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Sustained release film preparation for local administration comprising prostaglandin derivative as active ingredient
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
KR20030065831A (ko) 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
PT3494995T (pt) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
EP2322243A1 (en) * 2002-08-29 2011-05-18 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US6840529B2 (en) * 2002-10-17 2005-01-11 David B. Call Articulated pickup truck camper/trailer
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0415789D0 (en) 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
US7579505B2 (en) 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
WO2006072599A2 (en) * 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
WO2008102128A2 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
US20130274232A1 (en) 2010-07-16 2013-10-17 Cipla Limited Pharmaceutical Compositions
WO2012049444A1 (en) 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
EP2836198A2 (en) 2012-04-11 2015-02-18 Cipla Limited Pharmaceutical composition comprising arformoterol and fluticasone furoate
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations

Also Published As

Publication number Publication date
AU2011278096A1 (en) 2013-02-14
ZA201300718B (en) 2013-08-28
MX2013000642A (es) 2013-04-03
CA2805700A1 (en) 2012-01-19
NZ605920A (en) 2015-01-30
US11077124B2 (en) 2021-08-03
JP2018199684A (ja) 2018-12-20
US20210308150A1 (en) 2021-10-07
RU2568882C2 (ru) 2015-11-20
EP2593108A2 (en) 2013-05-22
BR112013001119A2 (pt) 2016-05-24
US20170333452A1 (en) 2017-11-23
US20130274232A1 (en) 2013-10-17
CN103096897A (zh) 2013-05-08
RU2013106866A (ru) 2014-08-27
AU2011278096B2 (en) 2014-08-28
EP3871676A1 (en) 2021-09-01
US12472190B2 (en) 2025-11-18
WO2012007729A3 (en) 2012-05-31
CN105412122A (zh) 2016-03-23
JP2017039736A (ja) 2017-02-23
US20130330281A1 (en) 2013-12-12
JP2013531056A (ja) 2013-08-01
CN110237260A (zh) 2019-09-17
WO2012007729A2 (en) 2012-01-19
KR20180091120A (ko) 2018-08-14

Similar Documents

Publication Publication Date Title
US12472190B2 (en) Pharmaceutical compositions
JP2019038818A (ja) 医薬組成物
JP2013542940A (ja) 医薬組成物
WO2014016548A2 (en) Pharmaceutical composition
JP2018058881A (ja) 医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170411

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171123

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180329

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170411

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180329

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180122

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170711

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180709

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180627

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180329

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180122

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20171123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170711

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170411

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180806